XML 60 R19.htm IDEA: XBRL DOCUMENT
v3.23.2

Stock-based Compensation | 3 Months Ended | 12 Months Ended
--- | --- | ---
Mar. 31, 2023 | Dec. 31, 2022
Share-Based Payment Arrangement [Abstract] |  |
Stock-based Compensation | 10. Stock-based compensation Stock options The below summary includes stock option activity within the Company’s 2014 Stock Incentive Plan and 2019 Incentive Award Plan for the three months ended March 31, 2023:
|  | Number of shares in Plans |  |  | Weighted average exercise price |  |  | Weighted average remaining contractual term (in years) |  |  | Aggregate intrinsic value |
Outstanding as of December 31, 2022 |  |  | 5,742,053 |  |  | $ | 2.35 |  |  |  | 6.69 |  |  | $ | 9,114 |
Granted |  |  | 27,350 |  |  |  | 4.66 |  |  |  | 8.61 |  |  |  | — |
Exercised |  |  | (2,969 | ) |  |  | 0.07 |  |  |  | — |  |  | $ | 1 |
Forfeited |  |  | (166,346 | ) |  |  | 2.20 |  |  |  | — |  |  |  | — |
Outstanding as of March 31, 2023 |  |  | 5,600,088 |  |  | $ | 2.36 |  |  |  | 5.63 |  |  | $ | 4 |
Options exercisable as of March 31, 2023 |  |  | 4,789,470 |  |  | $ | 2.40 |  |  |  | 5.29 |  |  | $ | 4 |
Options unvested as of March 31, 2023 |  |  | 810,618 |  |  | $ | 2.13 |  |  |  | 7.65 |  |  | $ | — |
The aggregate intrinsic value of stock options is calculated as the difference between the exercise price of the stock options and the fair value of the Company’s common stock for those stock options that had exercise prices lower than the fair value of the Company’s common stock. Stock option valuation The assumptions that the Company used to determine the grant-date fair value of stock options granted to employees and directors were as follows, presented on a weighted average basis:
|  | March 31, 2023 |
Risk-free interest rate |  |  | 3.6 | %
Expected term (in years) |  |  | 6.0 |
Expected volatility |  |  | 92.0 | %
Expected dividend yield |  |  | 0.0 | %
The weighted-average grant date fair value of options granted during the three months ended March 31, 2023 and 2022 was $3.58 and $3.55, respectively. The total grant date fair value of options vested during the three months ended March 31, 2023 and 2022 was $2,874 and $5,097, respectively. Repricing of stock options On August 17, 2022, the Board of Directors approved the repricing of all options granted under the 2019 Incentive Award Plan that were held by then current employees, executives, directors, and consultants for which the exercise price per share was greater than the closing price per share of the Company’s common stock on August 17, 2022 (Underwater Options) by reducing the exercise price of each Underwater Option to $2.14, the closing price per share of the Company’s common stock on August 17, 2022. Except for the modification of the exercise price, all other terms and conditions of the Underwater Options remain in effect. The option repricing resulted in incremental stock-based compensation of $2,505, of which $170 was recorded as expense in the three months ended March 31, 2023. At March 31, 2023, $705 incremental expense remains which will be recognized as expense over the requisite service period in which the options vest. Restricted stock units The below summary includes restricted stock unit activity within the Company’s 2019 Incentive Award Plan for the three months ended March 31, 2023:
|  | Number of shares |  |  | Weighted average fair value |
Unvested, December 31, 2022 |  |  | 3,101,650 |  |  | $ | 2.78 |
Awarded |  |  | 1,666,340 |  |  |  | 4.78 |
Vested |  |  | (306,775 | ) |  |  | 1.17 |
Forfeited |  |  | (819,050 | ) |  |  | 3.85 |
Unvested as of March 31, 2023 |  |  | 3,642,165 |  |  | $ | 3.59 |
Stock-based compensation The Company recognized stock-based compensation within the accompanying consolidated statements of operations as follows:
|  | Three Months Ended March 31, |
|  | 2023 |  |  | 2022 |
Research and development |  | $ | 839 |  |  | $ | 2,301 |
General and administrative |  |  | 2,592 |  |  |  | 2,965 |
Total |  | $ | 3,431 |  |  | $ | 5,266 |
As of March 31, 2023, total unrecognized stock-based compensation expense relating to unvested stock options and restricted stock units was $17,610. This amount is expected to be recognized over a weighted-average period of 1.72 years. | 9. Stock-based compensation On November 13, 2014, the Company adopted the 2014 Stock Incentive Plan (2014 Plan). All of the Company’s employees, officers, directors, and consultants are eligible to be granted options to purchase common shares and restricted stock under the terms of the 2014 Plan. The Company reserved an aggregate of 8,550,415 shares of common stock for issuance under the 2014 Plan. As of December 31, 2022, there were no shares of common stock available for future grants under the 2014 Plan. On September 17, 2019, the Company’s board of directors and on September 19, 2019, its stockholders approved and adopted the 2019 Incentive Award Plan (2019 Plan). Under the 2019 Plan, the Company may grant stock options, stock appreciation rights, restricted stock, restricted stock units, and other stock and cash-based awards to individuals who are then employees, officers, directors or consultants of the Company, and employees and consultants of the Company’s subsidiaries. A total of 3,100,000 shares of common stock were approved to be initially reserved for issuance under the 2019 plan. The number of shares under the 2014 Plan subject to outstanding awards as of the effective date of the 2019 Plan that are subsequently canceled, forfeited or repurchased by the Company will be added to the shares reserved under the 2019 Plan. In addition, the number of shares of common stock available for issuance under the 2019 Plan will be automatically increased on the first day of each calendar year during the ten-year term of the 2019 Plan, beginning with January 1, 2020 and ending with January 1, 2029, by the amount equal to 4% of the outstanding number of shares of the Company’s common stock on December 31 of the preceding calendar year or such lesser amount as determined by the Company’s board of directors. All stock option grants are non-statutory stock options except option grants to employees (including officers and directors) intended to qualify as incentive stock options under the Internal Revenue Code of 1986, as amended. Incentive stock options may not be granted at less than the fair market value of the Company’s common stock on the date of grant, as determined in good faith by the Board of Directors at its sole discretion. Nonqualified stock options may be granted at an exercise price established by the Board of Directors at its sole discretion (which has not been less than fair market value on the date of grant) and the vesting periods may vary. Vesting periods are generally four years and are determined by the Board of Directors. Stock options become exercisable as they vest. Options granted under the 2014 Plan and the 2019 Plan expire no more than ten years from the date of grant. Stock options A summary of the stock option activity under the 2014 Plan and the 2019 Plan are as follows:
|  | Number of shares |  |  | Weighted average exercise price (1) |  |  | Weighted average remaining contractual term (in years) |  |  | Aggregate intrinsic value |
Outstanding as of December 31, 2020 |  |  | 6,816,798 |  |  | $ | 10.11 |  |  |  | 8.45 |  |  | $ | 171,415 |
Granted |  |  | 1,357,426 |  |  |  | 32.76 |  |  |  | 8.07 |  |  |  | — |
Exercised |  |  | (642,314 | ) |  |  | 2.02 |  |  |  | — |  |  | $ | 11,652 |
Forfeited |  |  | (701,873 | ) |  |  | 16.48 |  |  |  | — |  |  |  | — |
Outstanding as of December 31, 2021 |  |  | 6,830,037 |  |  | $ | 5.35 |  |  |  | 7.76 |  |  | $ | 6,987 |
Granted |  |  | 221,176 |  |  |  | 1.78 |  |  |  | 8.32 |  |  |  | — |
Exercised |  |  | (10,047 | ) |  |  | 1.24 |  |  |  | — |  |  | $ | 37 |
Forfeited |  |  | (1,299,113 | ) |  |  | 18.04 |  |  |  | — |  |  |  | — |
Outstanding as of December 31, 2022 |  |  | 5,742,053 |  |  | $ | 2.35 |  |  |  | 6.69 |  |  | $ | 9,114 |
Options exercisable as of December 31, 2022 |  |  | 4,579,486 |  |  | $ | 2.40 |  |  |  | 6.39 |  |  | $ | 7,071 |
Options unvested as of December 31, 2022 |  |  | 1,162,567 |  |  | $ | 2.12 |  |  |  | 7.84 |  |  | $ | 2,043 |
The aggregate intrinsic value of stock options is calculated as the difference between the exercise price of the stock options and the fair value of the Company’s common stock for those stock options that had exercise prices lower than the fair value of the Company’s common stock. (1) On August 17, 2022, the Company’s Board of Directors approved the repricing of all options granted under the 2019 Incentive Award Plan that were held by then current employees, executives, directors, and consultants for which the exercise price per share was greater than the closing price per share of the Company’s common stock on August 17, 2022 (Underwater Options) by reducing the exercise price of each Underwater Option to $2.14, the closing price per share of the Company’s common stock on August 17, 2022. See “ Repricing of stock options ” section for more information. Stock option valuation The assumptions that the Company used to determine the grant-date fair value of stock options granted to employees and directors were as follows, presented on a weighted average basis:
|  | Year Ended December 31, |
|  | 2022 |  |  | 2021 |
Risk-free interest rate |  |  | 3.0 | % |  |  | 0.5 | %
Expected term (in years) |  |  | 6.0 |  |  |  | 6.0 |
Expected volatility |  |  | 80.0 | % |  |  | 79.8 | %
Expected dividend yield |  |  | 0.0 | % |  |  | 0.0 | %
The weighted-average grant date fair value of options granted to employees during the years ended December 31, 2022 and 2021 was $1.58 and $22.39 respectively. The total grant date fair value of options vested during the years ended December 31, 2022 and 2021 was $14,219 and $16,304, respectively. Repricing of stock options On August 17, 2022, the Board of Directors approved the repricing of each Underwater Option to $2.14, the closing price per share of the Company’s common stock on August 17, 2022. Except for the modification of the exercise price, all other terms and conditions of the Underwater Options remain in effect. The option repricing resulted in incremental stock-based compensation of $2,505, of which $1,630 was recorded as expense in the year ended December 31, 2022 and $875 will be recognized as expense over the remaining vesting period. Restricted stock units The below summary includes restricted stock unit activity within the Company’s 2019 Incentive Award Plan for the year ended December 31, 2022.
|  | Number of shares |  |  | Weighted average fair value |
Unvested, December 31, 2021 |  |  | 626,300 |  |  | $ | 9.54 |
Awarded |  |  | 3,576,650 |  |  |  | 3.01 |
Vested |  |  | (551,450 | ) |  |  | 9.54 |
Forfeited |  |  | (549,850 | ) |  |  | 5.06 |
Unvested, December 31, 2022 |  |  | 3,101,650 |  |  | $ | 2.80 |
Stock-based compensation Stock-based compensation expense of $19,831 and $21,750 for the years ended December 31, 2022 and 2021 respectively, is included in research and development and general and administrative expenses in the Company’s consolidated statements of operations and comprehensive loss. As of December 31, 2022 and 2021, total unrecognized stock-based compensation expense relating to unvested stock options and restricted stock units was $19,537 and $39,112, respectively. This amount is expected to be recognized over a weighted-average period of 1.55 years and 2.49 years, respectively.

X
- Definition The entire disclosure for share-based payment arrangement. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//718/tableOfContent Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2)(i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (l) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration